Biocon settles patent dispute with Genetech over cancer drug
In short
Biocon and Genetech signed a patent settlement deal over a cancer treatment drug.
The agreement is meant to end all pending disputes, including in the US and Canada. The earliest launch dates for the drug are not stated in the available reporting.
What the reporting says
Biocon and Genetech executed a patent settlement agreement to resolve all pending disputes between them, according to Biocon’s exchange filing cited in market coverage. The reporting says the settlement covers disputes in the US, Canada and other jurisdictions. The earliest secured launch dates for the cancer treatment drug are not provided in the available summary.
Why it matters
Biocon and Genetech executed a patent settlement agreement to resolve all pending disputes, including in the US, Canada and other jurisdictions, according to Biocon’s exchange filing cited in the summary. The event matters because it could clear the way for the cancer treatment drug’s launch timeline. The earliest secured launch dates and other commercial terms are not stated.